Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer

Nabin Raj Karki; Peyton McElhone; Natasha Savage; Nagla Abdel Karim

doi:10.1136/bcr-2021-243751

Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer

Nabin Raj Karki, Peyton McElhone, Natasha Savage, Nagla Abdel Karim

Research output: Contribution to journal › Article › peer-review

Abstract

A 65-year-old with non-small cell lung cancer developed autoimmune haemolytic anaemia while receiving pembrolizumab containing chemoimmunotherapy. Initially thought to be due to pembrolizumab induced haemolysis, he was treated with steroids, and pembrolizumab was held. Haemolysis was refractory to steroids and blood was observed to agglutinate in cold room temperatures. Cold agglutinins in high titre and monoclonal serum IgM kappa protein were detected. Bone marrow biopsy showed marginal zone lymphoma confirming low grade B-cell lymphoma causing cold agglutinin disease. B-cell depletion by rituximab stopped haemolysis, and pembrolizumab was safely continued for lung cancer.

Original language	English (US)
Journal	BMJ Case Reports
Volume	14
Issue number	8
DOIs	https://doi.org/10.1136/bcr-2021-243751
State	Published - Aug 16 2021

Keywords

haematology (incl blood transfusion)
immunology
lung cancer (oncology)

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bcr-2021-243751

Cite this

@article{1e96a07d9d694489a001ec12399029d5,

title = "Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer",

abstract = "A 65-year-old with non-small cell lung cancer developed autoimmune haemolytic anaemia while receiving pembrolizumab containing chemoimmunotherapy. Initially thought to be due to pembrolizumab induced haemolysis, he was treated with steroids, and pembrolizumab was held. Haemolysis was refractory to steroids and blood was observed to agglutinate in cold room temperatures. Cold agglutinins in high titre and monoclonal serum IgM kappa protein were detected. Bone marrow biopsy showed marginal zone lymphoma confirming low grade B-cell lymphoma causing cold agglutinin disease. B-cell depletion by rituximab stopped haemolysis, and pembrolizumab was safely continued for lung cancer.",

keywords = "haematology (incl blood transfusion), immunology, lung cancer (oncology)",

author = "Karki, {Nabin Raj} and Peyton McElhone and Natasha Savage and {Abdel Karim}, Nagla",

note = "Publisher Copyright: {\textcopyright} BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2021",

month = aug,

day = "16",

doi = "10.1136/bcr-2021-243751",

language = "English (US)",

volume = "14",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "8",

}

TY - JOUR

T1 - Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer

AU - Karki, Nabin Raj

AU - McElhone, Peyton

AU - Savage, Natasha

AU - Abdel Karim, Nagla

N1 - Publisher Copyright: © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/8/16

Y1 - 2021/8/16

N2 - A 65-year-old with non-small cell lung cancer developed autoimmune haemolytic anaemia while receiving pembrolizumab containing chemoimmunotherapy. Initially thought to be due to pembrolizumab induced haemolysis, he was treated with steroids, and pembrolizumab was held. Haemolysis was refractory to steroids and blood was observed to agglutinate in cold room temperatures. Cold agglutinins in high titre and monoclonal serum IgM kappa protein were detected. Bone marrow biopsy showed marginal zone lymphoma confirming low grade B-cell lymphoma causing cold agglutinin disease. B-cell depletion by rituximab stopped haemolysis, and pembrolizumab was safely continued for lung cancer.

AB - A 65-year-old with non-small cell lung cancer developed autoimmune haemolytic anaemia while receiving pembrolizumab containing chemoimmunotherapy. Initially thought to be due to pembrolizumab induced haemolysis, he was treated with steroids, and pembrolizumab was held. Haemolysis was refractory to steroids and blood was observed to agglutinate in cold room temperatures. Cold agglutinins in high titre and monoclonal serum IgM kappa protein were detected. Bone marrow biopsy showed marginal zone lymphoma confirming low grade B-cell lymphoma causing cold agglutinin disease. B-cell depletion by rituximab stopped haemolysis, and pembrolizumab was safely continued for lung cancer.

KW - haematology (incl blood transfusion)

KW - immunology

KW - lung cancer (oncology)

UR - http://www.scopus.com/inward/record.url?scp=85114405569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114405569&partnerID=8YFLogxK

U2 - 10.1136/bcr-2021-243751

DO - 10.1136/bcr-2021-243751

M3 - Article

C2 - 34400426

AN - SCOPUS:85114405569

SN - 1757-790X

VL - 14

JO - BMJ Case Reports

JF - BMJ Case Reports

IS - 8

ER -

Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this